Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Nov 20;8(11):e78972.
doi: 10.1371/journal.pone.0078972. eCollection 2013.

Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials

Yanzhi Song  1 , Xiaodong Li, Settipalli Pavithra, Dong Li
Affiliations
Meta-Analysis

Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials

Yanzhi Song et al. PLoS One. .

Abstract

Background: Venous thromboembolism (VTE) is a prevalent disease with potential serious consequences. Idraparinux and idrabiotaparinux are two kinds of long-acting pentasaccharides. Evidence has shown that idraparinux and idrabiotaparinux are effective anticoagulants. However, up to now, there is no consensus on whether they are better than other anticoagulation methods for long-term VTE treatment.

Objective: To evaluate the effect of idraparinux or idrabiotaparinux versus other anticoagulation methods for long-term VTE treatment.

Methods: We searched Cochrane Central Register of Controlled Trials, PubMed, Embase, Web of science, clinical trial registry web sites (clinical trials,WHO clinical trial registry), Googlescholar, PubMed related articles and companies' web sites electronically up to Dec 30(th), 2012 and manually searched the reference lists and conference proceedings. Only randomized controlled trial (RCT) involving adult patients comparing idraparinux and/or idrabiotaparinux versus other anticoagulation methods for long-term VTE treatment was included. Two reviewers evaluated the studies and extracted data independently. Pooled risk ratios (RRs) were calculated as outcome measures and Revman 5.2 software was used to analyze data. Our primary efficacy and safety outcomes were the recurrent VTE and major bleeding rates.

Results: We included four RCTs and involved 8584 participants on idraparinux or idrabiotaparinux versus standard warfarin for VTE treatment from 9364 references. We did not perform meta-analysis on the VTE rate because of the significant heterogeneity. We used the fixed effect model to analyze the safety outcomes and demonstrated that idraparinux or idrabiotaparinux decreased major bleeding rate significantly (RR 0.73, 95% CI 0.54 to 0.98, P = 0.04) but had a trend to increase the all cause mortality (RR 1.26, 95% CI 1.00 to 1.57, P = 0.05) compared with warfarin.

Conclusions: Until now there is not sufficient evidence to clarify whether idraparinux or idrabiotaparinux is as effective and safe as the standard warfarin treatment for VTE treatment.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow diagram of screening studies for inclusion in systematic review.
Figure 2
Figure 2. Efficacy of idraparinux or idrabiotaparinux versus standard warfarin treatment.
Figure 3
Figure 3. Efficacy medicine subgroup analysis.
Figure 4
Figure 4. Safety of of idraparinux or idrabiotaparinux versus standard warfarin treatment.
Figure 5
Figure 5. Major bleeding medicine subgroup analysis.
Figure 6
Figure 6. Mortality medicine subgroup analysis.
See this image and copyright information in PMC

References

    1. Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, et al. (2001) Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clinic Proceedings 76: 1102–1110. - PubMed
    1. Heit JA, et al.. (2005) Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 106: abstract #910, p. 267a.
    1. Agnelli G, Sonaglia F (2000) Prevention of venous thromboembolism. Thromb Res 97: V49–62. - PubMed
    1. Geerts W, Bergqvist D, Pineo GF, Heit JA, Samama CM, et al. (2008) Prevention of Venous Thromboembolism: American College of Chest PHysicians Evidence-Based Clinical Practive Guidelines (8th Edition). Chest 133: 381S–453S. - PubMed
    1. Veyrat-Follet C, Vivier N, Trellu M, Dubruc C, Sanderink GJ (2009) The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. Journal of Thrombosis and Haemostasis 7: 559–565. - PubMed

MeSH terms